Background: Objectives of the study was to describe the utilization pattern of systemic antifungal agents in Indian patients with invasive fungal infections (IFIs).Methods: This real-world, multicenter (127 centers), retrospective analysis included data of patients receiving systemic antifungal medications at various centers across India. The study data was collected between April 2021 and March 2022.Results: Data of a total of 323 patients was analyzed. The mean age of patients was 54±13.52 years. There was male preponderance seen in this study (72.4%). Diabetes was the most common comorbidity (36.8%) followed by concomitant diabetes and hypertension (31.9%), hypertension (9.6%) and hematological malignancies (9.6%). The most common indication occurring in >10% of the patients and for whom systemic antifungals were used included pulmonary mucormycosis (33.1%) followed by invasive candidiasis (16.1%), sepsis (13.3%) and fungal pneumonia (11.8%). In total 323 patients, the most common antifungal drug prescribed was posaconazole (38.6%) followed by anidulafungin (32.8%), caspofungin (10.5%), fluconazole (9.3%) and micafungin (8.7%). Posaconazole was most commonly used for pulmonary mucormycosis (84.8%), fluconazole for sepsis (33.3%), caspofungin for fungal pneumonia (23.5%) and anidulafungin (33.1%), and micafungin (39.3%) for invasive candidiasis.Conclusions: This study provides real-world evidence on the demographics of Indian patients with IFIs and utilization pattern of systemic antifungals by health care physicians in clinical practice.
<p><strong>Background:</strong> To describe the patient characteristics and usage pattern of biosimilar bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in India.</p><p><strong>Methods:</strong> This real-world, retrospective analysis included adult patients receiving biosimilar bevacizumab between April 2021 and March 2022.</p><p><strong>Results:</strong> A total of 1125 patients with mCRC who received biosimilar bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 years. Majority of the patients were males (71%) and belonged to the age groups of 41-76 years. The primary tumor site was right colon (52.6%) followed by left colon (29.2%) and rectum (17.3%), and the tumor grade was reported as high in most (88.7%) of the patients. Majority of patients received biosimilar bevacizumab-based chemotherapy as first-line therapy (61.3%), followed by second-line (31.9%) and third-line therapy (6.8%). In combination with biosimilar bevacizumab, FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) was the most commonly administered regimen (42.9%), followed by CAPOX (capecitabine and oxaliplatin, 26.5%) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan, 22.8%).</p><p><strong>Conclusions:</strong> Biosimilar bevacizumab-based chemotherapy is being widely used in real‑world clinical setting in India for the management of patients with mCRC.</p>
Background: To describe treatment patterns, patient characteristics and usage pattern of biosimilar rituximab for the treatment of non-Hodgkin lymphomas (NHL) in India.Methods: This real-world, retrospective, analysis included adult patients receiving rituximab biosimilar between April 2021 and March 2022.Results: A total of 750 patients with NHL who received biosimilar rituximab were included. The most common indications reported in this analysis were diffuse large cell B-cell lymphoma [DLBCL, 64.5% (n=484)], follicular lymphoma, [FL, 23.7% (n=178)], and mantle cell lymphoma [MCL, 5.3% (n=40)]; other subtypes constituted 6.4% of the patients (n=48). The mean age of patients among DLBCL, FL and MCL was 65.5, 55.3 and 57 years, respectively. Across the lymphomas, >90% of the patients received R-chemo as first-line therapy. R-CHOP was the most common regimen across indications.Conclusions: Biosimilar rituximab-based chemotherapy is being adopted in real‑world clinical practice in India for the management of patients with B-cell NHL including DLBCL, FL, MCL and other lymphomas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.